Medicenna's Key Participation at Investment Conference
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage cancer immunotherapy company specializing in the development of Superkines, is set to make an impactful presence at the H.C. Wainwright Annual Global Investment Conference. This critical event aims to showcase the innovations and advancements in the field of cancer therapy.
About the Conference
The H.C. Wainwright 27th Annual Global Investment Conference will occur over three days, from September 8 to September 10, 2025. Dr. Fahar Merchant, the President and CEO of Medicenna, is scheduled to deliver a key presentation and engage in one-on-one meetings during the conference, facilitating vital discussions around the future of cancer immunotherapy.
Presentation Details
Attendees of the conference can look forward to Dr. Merchant's presentation on September 9, 2025, from 2:30 PM to 3:00 PM (Eastern Standard Time). The location for this key presentation is the Lotte New York Palace Hotel, providing an excellent opportunity for insights into Medicenna's forward-thinking strategies in immunotherapy.
How to Participate
For those interested in attending or scheduling a one-on-one meeting with Dr. Merchant, it is advisable to register for the conference or reach out to H.C. Wainwright representatives. This interaction offers investors a chance to gain deeper insights into Medicenna’s vision and upcoming projects.
Insights Into Medicenna's Innovations
Medicenna is at the forefront of developing innovative cancer treatments through their proprietary Superkine technology. Their leading candidate, MDNA11, represents a next-generation growth factor that targets CD122, thereby preferentially activating T cells and natural killer (NK) cells, which are pivotal in fighting cancer.
Research and Clinical Trials
The firm is also advancing its IL-4 empowered Superkine, bizaxofusp (previously known as MDNA55). It has undergone extensive research with over 130 patients enrolled in five clinical trials, addressing aggressive forms of brain cancer, particularly recurrent glioblastoma multiforme (GBM). Notably, bizaxofusp has secured Fast Track and Orphan Drug Designation from regulatory bodies, underscoring its potential impact.
Future Directions and Development
Medicenna is committed to enhancing its pipeline with biSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs aimed at treating tumors that are non-responsive to current immunotherapies. These innovative approaches showcase Medicenna’s relentless pursuit of developing effective treatments for the most challenging cancers.
Contact Information for Investors
For more details about Medicenna's participation and innovative research, interested parties can reach out to the Investor Relations team. Shushu Feng is available to provide further updates and answer inquiries regarding Medicenna's current and future endeavors.
Investor Relations Contact:
Shushu Feng
Investor Relations, Medicenna Therapeutics
(416) 964-5442
ir@medicenna.com
Frequently Asked Questions
What is the purpose of Medicenna’s participation in the conference?
Medicenna aims to showcase its innovative cancer therapies and engage with investors and stakeholders to further its mission in the immunotherapy space.
Where will the conference take place?
The H.C. Wainwright 27th Annual Global Investment Conference will take place at the Lotte New York Palace Hotel in New York City.
Who is presenting on behalf of Medicenna?
Dr. Fahar Merchant, the President and CEO of Medicenna, will present and participate in discussions during the conference.
What are Superkines?
Superkines are engineered proteins that have been developed to selectively enhance immune responses against cancer, promoting better targeting of tumors.
How can investors learn more about Medicenna's developments?
Investors can find more information on Medicenna’s official website or contact its Investor Relations for the latest updates and opportunities.
